Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D. скачать в хорошем качестве

Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast... Spotify - https://open.spotify.com/show/5NhjpDe... YouTube -    • The Business Of Biotech Podcast